17. Shim, H. et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl.
Acad. Sci. USA 94, 6658–6663 (1997).
18. Fantin, V.R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425–434 (2006).
19. Qing, G. et al. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia
inducible factor HIF-1alpha. Cancer Res. 70, 10351–10361 (2010).
20. Yu, Y. et al. Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochem.
Pharmacol. 62, 81–89 (2001).
21. Le, A. et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression.
Proc. Natl. Acad. Sci. USA 107, 2037–2042 (2010).
22. Granchi, C. et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A
(LDH-A) as starvation agents against cancer cells. J. Med. Chem. 54, 1599–1612 (2011).
23. Bonnet, S. et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes
apoptosis and inhibits cancer growth. Cancer Cell 11, 37–51 (2007).
24. Michelakis, E.D. et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med. 2,
31ra34 (2010).
25. Cairns, R.A., Papandreou, I., Sutphin, P.D. & Denko, N.C. Metabolic targeting of hypoxia and HIF1 in solid
tumors can enhance cytotoxic chemotherapy. Proc. Natl. Acad. Sci. USA 104, 9445–9450 (2007).
26. Dimmer, K.S., Friedrich, B., Lang, F., Deitmer, J.W. & Broer, S. The low-affinity monocarboxylate transporter
MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem. J. 350, 219–227 (2000).
27. Gallagher, S.M., Castorino, J.J., Wang, D. & Philp, N.J. Monocarboxylate transporter 4 regulates maturation
and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 67, 4182–4189 (2007).
28. Vegran, F., Boidot, R., Michiels, C., Sonveaux, P. & Feron, O. Lactate influx through the endothelial cell
monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 71, 2550–2560 (2011).
29. Bueno, V. et al. The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel
immunosuppressant, prolongs allograft survival in the mouse. Transplantation 84, 1204–1207 (2007).
30. Sonveaux, P. et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin.
Invest. 118, 3930–3942 (2008).
31. Vander Heiden, M.G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10,
671–684 (2011).
32. Wise, D.R. et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of
alpha-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. USA 108, 19611–19616 (2011).
33. Metallo, C.M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature
481, 380–384 (2012).
34. Mullen, A.R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria.
Nature 481, 385–388 (2012).
35. Wise, D.R. et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and
leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 105, 18782–18787 (2008).
36. Gao, P. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and
glutamine metabolism. Nature 458, 762–765 (2009).
37. Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R. & Lazebnik, Y. Deficiency in glutamine but not
glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 178, 93–105 (2007).
38. Yuneva, M.O. et al. The metabolic profile of tumors depends on both the responsible genetic lesion and
tissue type. Cell Metab. 15, 157–170 (2012).
39. Hu, W. et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function.
Proc. Natl. Acad. Sci. USA 107, 7455–7460 (2010).
40. Wang, J.B. et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell
18, 207–219 (2010).
41. Cassago, A. et al. Mitochondrial localization and structure-based phosphate activation mechanism of
Glutaminase C with implications for cancer metabolism. Proc. Natl. Acad. Sci. USA 109, 1092–1097 (2012).
42. Kita, K., Suzuki, T. & Ochi, T. Diphenylarsinic acid promotes degradation of glutaminase C by mitochondrial
Lon protease. J. Biol. Chem. 287, 18163–18172 (2012).
43. Ahluwalia, G.S., Grem, J.L., Hao, Z. & Cooney, D.A. Metabolism and action of amino acid analog
anti-cancer agents. Pharmacol. Ther. 46, 243–271 (1990).
44. Robinson, M.M. et al. Novel mechanism of inhibition of rat kidney-type glutaminase by
bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 406, 407–414 (2007).
45. Le, A. et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B
cells. Cell Metab. 15, 110–121 (2012).
46. Yang, C. et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose
metabolism or Akt signaling. Cancer Res. 69, 7986–7993 (2009).
47. Peng, G., Dixon, D.A., Muga, S.J., Smith, T.J. & Wargovich, M.J. Green tea polyphenol
(-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol. Carcinog. 45, 309–319 (2006).
48. Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast
cancer. Nature 476, 346–350 (2011).
49. Locasale, J.W. et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to
oncogenesis. Nat. Genet. 43, 869–874 (2011).
50. Tibbetts, A.S. & Appling, D.R. Compartmentalization of Mammalian folate-mediated one-carbon metabolism.
Annu. Rev. Nutr. 30, 57–81 (2010).
51.
(1999). 52.
Liang, X.H. et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402, 672–676
Qu, X. et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin.
Invest. 112, 1809–1820 (2003).
0. 1. 2. 3. 53.
CAS ISI PubMed Article
Liang, C. et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat.
Cell Biol. 8, 688–699 (2006).
0. 1. 2. 3. 54. 0. 1. 2. 3. 55.
(2009). 0. 1. 2.
CAS ISI PubMed Article
Takamura, A. et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 25, 795–800 (2011).
CAS ISI PubMed Article
Mathew, R. et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 137, 1062–1075
CAS ISI PubMed
3. 56.
Article
Lau, A. et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction
between Keap1 and p62. Mol. Cell. Biol. 30, 3275–3285 (2010).
0. 1. 2. 57.
CAS PubMed Article
Lum, J.J. et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120,
237–248 (2005).
0. 1. 2. 3. 58.
CAS ISI PubMed Article
Degenhardt, K. et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and
tumorigenesis. Cancer Cell 10, 51–64 (2006).
0. 1. 2. 3. 59.
CAS ISI PubMed Article
Mathew, R. et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev.
21, 1367–1381 (2007).
0. 1. 2. 3. 60.
CAS ISI PubMed Article
Karantza-Wadsworth, V. et al. Autophagy mitigates metabolic stress and genome damage in mammary
tumorigenesis. Genes Dev. 21, 1621–1635 (2007).
0. 1. 2. 3.
CAS ISI PubMed Article
相关推荐：
loading